Lyra Therapeutics Financial Health

Short Term Liabilities: LYRA's short term assets ($112.2M) exceed its short term liabilities ($13.6M).

Long Term Liabilities: LYRA's short term assets ($112.2M) exceed its long term liabilities ($12.6M).

Debt Level: LYRA is debt free.

Reducing Debt: LYRA has not had any debt for past 5 years.

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: LYRA has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: LYRA has sufficient cash runway for 1.6 years if free cash flow continues to reduce at historical rates of 38.3% each year.

• Healthy companies in the Pharmaceuticals & Biotech industry.